SCHEMBL21685914

SCHEMBL21685914

CC(C)(C)OC(=O)N[C@@H]1C(=O)N(Cc2ccccc2)C[C@@H]1CF

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ SCN9A Q15858 3/20 0.45
▸ CCKBR P32239 2/20 0.41
▸ SIRT5 Q9NXA8 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ NPFFR1 Q9GZQ6 1/20 0.39
▸ NPFFR2 Q9Y5X5 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MTNR1A P48039 1/20 0.38
▸ MTNR1B P49286 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722497 1.00 KMT2A (0.49) KMT2AL3MBTL1SCN9ACCKBRSIRT5
SCHEMBL20722883 0.84 CCKBR (0.47) KMT2ACCKBRSIRT5MEN1ALDH1A1
SCHEMBL6948329 0.79 KMT2A (0.42) KMT2AL3MBTL1SCN9AMAPK1
SCHEMBL6948325 0.79 KMT2A (0.42) KMT2AL3MBTL1SCN9AMAPK1
SCHEMBL6948326 0.79 KMT2A (0.42) KMT2AL3MBTL1SCN9AMAPK1
SCHEMBL3190069 0.79 KMT2A (0.52) KMT2AL3MBTL1SCN9AMEN1ALDH1A1
SCHEMBL3190060 0.79 KMT2A (0.52) KMT2AL3MBTL1SCN9AMEN1ALDH1A1
SCHEMBL21684765 0.78 KMT2A (0.51) KMT2AL3MBTL1SCN9AMEN1NPFFR1
SCHEMBL376613 0.78 KMT2A (0.51) KMT2AL3MBTL1SCN9AMEN1NPFFR1
SCHEMBL20722866 0.78 KMT2A (0.51) KMT2AL3MBTL1SCN9AMEN1NPFFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 — — US disclosed
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 — — CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 — — US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 — — US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 — — US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 — — US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 — — EP disclosed
CN-112867712-A Carboxamides as ubiquitin-specific protease inhibitors 瓦洛早期发现股份有限公司 2021-05-28 — — CN disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KMT2A 339/4885L3MBTL1 1885/4885SCN9A 4471/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 KMT2A 339/4885L3MBTL1 1885/4885SCN9A 4471/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KMT2A 339/4885L3MBTL1 1885/4885SCN9A 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback